glp 1 vs glp 3 Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Blood Sugar Levels Supply Options:6 Month Supply Comparing Semaglutide, Liraglutide, and

glp 1 vs glp 3 Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Blood Sugar Levels Supply Options:6 Month Supply Comparing Semaglutide, Liraglutide, and

Comparing Semaglutide, Liraglutide, and Tirzepatide: Key Insights

2024;26(Suppl 4):16–27

Blood Sugar Levels

Supply Options:6 Month Supply

Unlike earlier GLP-1 receptor agonists, retatrutide is a triple agonist : GLP-1 receptor agonist – suppresses appetite, slows gastric emptying, improves insulin sensitivity GIP receptor agonist – enhances insulin release, amplifies GLP-1 effects Glucagon receptor agonist – stimulates energy expenditure, fat metabolism, and potentially impacts lipid handling Clinical trials so far have shown remarkable weight loss (up to 24% in some studies) and strong metabolic improvements, including effects on lipids like LDL cholesterol